Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice

Diabetes

Volumn 60, Issue 2, 2011, Pages 391-397

  Lee, Young ^a   Wang, May Yun ^a   Du, Xiu Quan ^b   Charron, Maureen J ^b   Unger, Roger H ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FATTY ACID; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; KETONE; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYLASE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CELL DESTRUCTION; CELL HYPERPLASIA; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GENE INACTIVATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PHENOTYPE; POLYURIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STREPTOZOCIN DIABETES; WILD TYPE;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; GLUCAGON; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIVER; MICE; MICE, KNOCKOUT; PANCREAS; RADIOIMMUNOASSAY; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79551600048     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0426     Document Type: Article

References (45)

1. Unger RH, Eisentraut AM, McCall MS, Leller S, Lanz HC, Madison LL. Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 1959;102:621-623
2. Unger RH, Eisentraut AM, McCall MS, Madison LL. Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest 1962;41:682-689
3. Baum J, Simons BE Jr, Unger RH, Madison LL. Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. Diabetes 1962;11:371-374
4. Unger RH, Eisentraut AM, Madison LL. The effects of total starvation upon the levels of circulating glucagon and insulin in man. J Clin Invest 1963;42:1031-1039
5. Müller WA, Faloona GR, Unger RH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 1973;54:52-57
6. Rivier J, Brazeau P, Vale W, et al. Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine. C R Acad Sci Hebd Seances Acad Sci D 1973;276:2737-2740
7. Dobbs R, Sakurai H, Sasaki H, et al. Glucagon: role in the hyperglycemia of diabetes mellitus. Science 1975;187:544-547
8. Gerich JE, Lorenzi M, Bier DM, et al. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 1975;292:985-989
9. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med 1978;299:433-436
10. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14-16
11. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010;107:4813-4819
12. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008;105:14070-14075
13. Brand CL, Jørgensen PN, Svendsen I, Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996;45:1076-1083
14. Djuric SW, Grihalde N, Lin CW. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. Curr Opin Investig Drugs 2002;3:1617-1623
15. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982;215:1115-1116
16. Parker JC, McPherson RK, Andrews KM, et al. Effects of skyrin, a receptor- selective glucagon antagonist, in rat and human hepatocytes. Diabetes 2000;49:2079-2086
17. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001;44:2018-2024
18. Qureshi SA, Rios Candelore M, Xie D, et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004;53: 3267-3273
19. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003;100:1438-1443
20. Liang Y, Osborne MC, Monia BP, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004;53:410-417
21. Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1- mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113:1571-1581
22. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984;74:2296-2299
23. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 2010;11:11-22
24. Conarello SL, Jiang G, Mu J, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007;50:142-150
25. Wang MY, Orci L, Ravazzola M, Unger RH. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci USA 2005;102:18011-18016
26. Orci L, Baetens D, Rufener C, et al. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci USA 1976; 73:1338-1342
27. Beale E, Andreone T, Koch S, Granner M, Granner D. Insulin and glucagon regulate cytosolic phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver. Diabetes 1984;33:328-332
28. Meier JM, McGarry JD, Faloona GR, Unger RH, Foster DW. Studies of the development of diabetic ketosis in the rat. J Lipid Res 1972;13:228-233
29. Christ B, Nath A, Jungermann K. Mechanism of the inhibition by insulin of the glucagon-dependent activation of the phosphoenolpyruvate carboxykinase gene in rat hepatocyte cultures. Action on gene transcription, mRNA level and -stability as well as hysteresis effect. Biol Chem Hoppe Seyler 1990;371:395-402
30. Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, Montminy M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 2003;426:190-193
31. Boden G, Rezvani I, Owen OE. Effects of glucagon on plasma amino acids. J Clin Invest 1984;73:785-793
32. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009;150:1155-1164
33. Almdal TP, Heindorff H, Bardram L, Vilstrup H. Increased amino acid clearance and urea synthesis in a patient with glucagonoma. Gut 1990;31:946-948
34. Norton JA, Kahn CR, Schiebinger R, Gorschboth C, Brennan MF. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med 1979;91:213-215
35. Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002;282:E419-E427
36. Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 1997;273:E488-E496
37. Ravazzola M, Unger RH, Orci L. Demonstration of glucagon in the stomach of human fetuses. Diabetes 1981;30:879-882
38. Bajorunas DR, Fortner JG, Jaspan JB. Glucagon immunoreactivity and chromatographic profiles in pancreatectomized humans. Paradoxical response to oral glucose. Diabetes 1986;35:886-893
39. Del Prato S, Riva F, Devidé A, Nosadini R, Fedele D, Tiengo A. Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis. Acta Diabetol Lat 1980;17: 111-118
40. Mashiter K, Harding PE, Chou M, et al. Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs. Endocrinology 1975;96:678-693
41. Matsuyama T, Wider MD, Tanaka R, et al. A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin. Diabete Metab 1979;5:141-147
42. Sudo T, Suzuki T, Tobe T. Changes in plasma glucagon after total pancreatectomy in man. Gastroenterol Jpn 1980;15:464-468
43. Tanjoh K, Tomita R, Fukuzawa M, Hayashi N. Peculiar glucagon processing in the intestine is the genesis of the paradoxical rise of serum pancreatic glucagon in patients after total pancreatectomy. Hepatogastroenterology 2003;50:535-540
44. Ross G, Lickley L, Vranic M. Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs. Am J Physiol 1978;234:E213-E219 (Pubitemid 9166819)
45. Rivera N, Everett-Grueter CA, Edgerton DS, et al. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther 2007;321:743-752